Skip to main content


Log in

Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript


Cardiovascular risk factors (CVRFs) have been related to poorer responses to systemic therapy in psoriatic arthritis (PsA). We aimed to evaluate the potential association between CVRFs and the achievement of therapeutic goals in PsA patients receiving systemic therapy. A cross-sectional study was carried out at 25 rheumatology outpatient clinics in Spain. PsA patients with established disease who were treated with conventional and biologic systemic therapies were included. The treatment goals measured were minimal disease activity (MDA) and very low disease activity (VLDA) responses. The relationship between MDA/VLDA and CVRFs was evaluated by uni- and multivariate models. Of a total of 227 patients, 133 (58.6%) and 26 (11.5%) patients were in MDA and VLDA, respectively. Tobacco use (crude OR 0.54), sedentary lifestyle (crude OR 1.95), hyperuricemia (crude OR 2.01) and obesity (crude OR 1.54) were related to the likelihood of MDA in the univariate model (p < 0.25), while in multivariate analysis, a sedentary lifestyle (OR 3.13, 95%CI 1.50–6.53; p = 0.002) increased the odds of having reached MDA. Obesity (crude OR 2.2) and dyslipidaemia (crude OR 1.80) were associated with VLDA in univariate analysis, whereas dyslipidaemia (OR 5.3, 95%CI 1.7–16.6; p = 0.004) increased the odds of VLDA in the multivariate model. We found no association between the number of CVRFs and the MDA/VLDA responses. In this cross-sectional, multicentre study, we could not find any relationship between CVRFs and lower odds of achieving stringent therapeutic goals in PsA. In any case, patients with psoriatic disease should be encouraged to maintain healthy lifestyle habits.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  1. Orbai AM, Ogdie A (2016) Patient-reported outcomes in psoriatic arthritis. Rheum Dis Clin N Am 42(2):265–283.

    Article  Google Scholar 

  2. Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am 41(4):545–568.

    Article  Google Scholar 

  3. Husni ME (2015) Comorbidities in psoriatic arthritis. Rheum Dis Clin N Am 41(4):677–698.

    Article  Google Scholar 

  4. Yim KM, Armstrong AW (2017) Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. Rheumatol Int 37(1):97–105.

    Article  CAS  PubMed  Google Scholar 

  5. Alonso S, Tejón P, Sarasqueta C, Coto P, Alperi M, Queiro R (2016) Age at disease onset may help to further characterize the disease phenotype in psoriatic arthritis. Joint Bone Spine 83(5):533–537.

    Article  CAS  PubMed  Google Scholar 

  6. Tejón P, Morante I, Cabezas I, Sarasqueta C, Coto P, Queiro R (2016) A polyarticular onset and diabetes could be the main predictors of cardiovascular events in psoriatic arthritis. Clin Exp Rheumatol 34(2):276–281

    PubMed  Google Scholar 

  7. González-Juanatey C, Llorca J, Amigo-Díaz E, Dierssen T, Martín J, González-Gay MA (2007) High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57(6):1074–1080.

    Article  PubMed  Google Scholar 

  8. Ogdie A, Yu Y, Haynes K et al (2015) Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 74(2):326–332.

    Article  PubMed  Google Scholar 

  9. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480–489.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lupoli R, Pizzicato P, Scalera A et al (2016) Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther 13(18):297

    Article  Google Scholar 

  11. di Minno MN, Peluso R, Iervolino S, et al (2013) Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 65:141–147

  12. Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD (2015) Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 74(5):813–817.

    Article  PubMed  Google Scholar 

  13. Batalla A, González-Fernández D, González-Lara L et al (2015) Cardiovascular risk factors influence response to biological therapies in psoriasis. J Am Acad Dermatol 73:327–329

    Article  PubMed  Google Scholar 

  14. Di Minno MN, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R, CaRRDs Study Group (2014) Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis 73:1157–1162

    Article  PubMed  Google Scholar 

  15. Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch F, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, Heijde D (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 77(1):3–17.

    Article  PubMed  Google Scholar 

  16. Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(01):48–53.

    Article  CAS  PubMed  Google Scholar 

  17. Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O'Dwyer JL, Meads DM, Emery P, Conaghan PG, Helliwell PS (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 386(10012):2489–2498.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Coates LC, Helliwell PS (2016) Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol 43(2):371–375.

    Article  CAS  PubMed  Google Scholar 

  19. Kavanaugh A, van der Heijde D, Beutler A et al (2016) Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res (Hoboken) 68:267–274

    Article  CAS  Google Scholar 

  20. Queiro R, Cañete JD, Montilla C et al (2017) Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther 29(19):72

    Article  Google Scholar 

  21. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673

    Article  PubMed  Google Scholar 

  22. Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, EULAR PsAID Taskforce (2014) A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 73:1012–1019

    Article  PubMed  Google Scholar 

  23. Cañete JD, Mease P (2012) The link between obesity and psoriatic arthritis. Ann Rheum Dis 71(8):1265–1266.

    Article  PubMed  Google Scholar 

  24. Ogdie A, Eder L (2015) Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis. Int J Clin Rheumatol 10(6):451–459.

    Article  CAS  Google Scholar 

  25. Ogdie A, Gelfand JM (2015) Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: a review of available evidence. Curr Rheumatol Rep 17(10):64.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Chimenti MS, Triggianese P, Conigliaro P, Santoro M, Lucchetti R, Perricone R (2014) Self-reported adherence to a home-based exercise program among patients affected by psoriatic arthritis with minimal disease activity. Drug Dev Res 75(Suppl 1):S57–S59.

    Article  CAS  PubMed  Google Scholar 

  27. Jacques P, McGonagle D (2014) The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it. Best Pract Res Clin Rheumatol 28(5):703–710.

    Article  PubMed  Google Scholar 

Download references


The authors would like to thank the MAAPs study group: C.A. Montilla; M.A. Abad; A. Cabez; S. Gómez; J.C. Torre Alonso; J. A Román Ivorra; J. Sanz; J. Salvatierra; J. Calvo Alén; A. Sellas; F.J. Rodriguez; A. Bermúdez; M. Romero; M. Riesco; J.C Cobeta; F. Medina; A. Aragón; ML. García; A. Urruticoechea; CM. González; E. Judez; B. González; P. Fernández; L. Pantoja; R. Morlá.


This work was funded by Pfizer.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Rubén Queiro.

Ethics declarations

All patients provided written informed consent. In accordance with the Spanish recommendations, the study was approved by the Clinical Research Ethics Committee of La Fe Hospital [(ref number FPNT-07-14-EO (C)] and was conducted in accordance with the principles contained in the Declaration of Helsinki for studies in humans.



Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Queiro, R., Cañete, J.D. Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?. Clin Rheumatol 37, 661–666 (2018).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: